Transgene S.A. (Euronext: TNG)

http://www.transgene.fr

Twitter: @TransgeneSA

Transgene is a France-based biopharmaceutical company focused on the development of therapeutic vaccines and immunotherapeutic products in oncology and infectious diseases. The Company has four compounds in Phase II clinical trials: TG4010, JX594/TG6006, TG4001/RG3484 and TG4040 and one compound in Phase I clinical trial: TG4023. Transgene has entered into strategic collaborative agreements for the development of two of its immunotherapy products: - An option agreement with Novartis for an exclusive license to develop TG4010 for the treatment of various cancers, including non small cell lung cancer (NSCLC) - An in-licensing agreement with US-based Jennerex Biotherapeutics, Inc., to develop and market JX594 (JX594/TG6006), an oncolytic product. Transgene has bio-manufacturing capacities for viral-based vectors. *

	Start	1979-01-01 established
	Group	Mérieux (Group)
	Industry	therapeutic vaccine
	Industry 2	immunotherapy
	Person	Archinard, Philippe (Transgene 200512 CEO)

	Region	Strasbourg
	Country	France
	Street	Boulevard Gonthier d’Andernach Parc d’Innovation d’Illkirch
	City	67405 Illkirch
	Tel	+33-3-8827-9100
		Address record changed: 2018-07-24

Basic data	Employees	D: 101 to 500 (2006-12-31)
	Currency	EUR
	Annual sales	28,019,000 (revenues, total (2007) 2007-12-31)
	Profit	-5,521,000 (2007-12-31)
	Cash	84,100,000 (2014-09-30)

		* Document for ï¿½About Sectionï¿½: Transgene S.A.. (3/31/11). "Press Release: Transgene Announces Completion of Enrolment in HCVac (Phase II Trial) of TG4040 for the Treatment of Chronic Hepatitis C". Illkirch.

		Record changed: 2020-01-05